John C. Jacobs - 03 Mar 2026 Form 4 Insider Report for NOVAVAX INC (NVAX)

Reporting relationship: President and CEO, Director
Issuer ticker: NVAX
Reported as of: 03 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Mar 2026, 06:03:17 UTC
Prior SEC filing: 09 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark J. Casey, Attorney-in-Fact

Key filing fact

John C. Jacobs filed Form 4 for NOVAVAX INC (NVAX) on 05 Mar 2026.

Key facts

This page summarizes John C. Jacobs's Form 4 filing for NOVAVAX INC (NVAX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Mar 2026, 06:03.

Change

Previous filing in this sequence was filed on 09 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001820836 Primary reporting owner

Jacobs John C

Relationship: President and CEO, Director
Address: 21 FIRSTFIELD ROAD, GAITHERSBURG
Signature: /s/ Mark J. Casey, Attorney-in-Fact
Signature date: 05 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVAX transaction

Common Stock

Options Exercise

Transaction value
Shares: +150,167
Change %: +132%
Price: $0.000000^*
Shares after: 264,130
Date: 03 Mar 2026
Ownership: Direct

NVAX transaction

Common Stock

Tax liability

Transaction value
Shares: -69,288
Change %: -23%
Price: $9.49^*
Shares after: 225,680
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NVAX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -150,167
Change %: -33%
Price: $0.000000^*
Shares after: 300,333
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,167
Exercise price: $0.000000
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.

Footnote F2

One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, (the "Plan") vest on each of the first three (3) anniversaries of March 3, 2025, in each case subject to continued employment through such vesting date.